Improved strategies and new treatment options for allergic rhinitis.
Primary principles relevant to the clinical management of allergic rhinitis include (1) avoidance of allergens and triggering factors, (2) use of appropriate pharmacotherapy, (3) evaluation regarding need for and appropriate use of immunotherapy, and (4) patient education and follow-up. Currently available pharmacotherapeutic options include oral and topical (intranasal) decongestants and corticosteroids, mast cell stabilizers, intranasal anticholinergics, and antihistamines. Future therapeutic options include leukotriene modifiers and anti-IgE antibodies.
Willsie
Sandra K
SK
University of Health Sciences-College of Osteopathic Medicine in Kansas City, MO, USA. swillsie@uhs.edu
D000281:Administration, Intranasal; D001507:Beclomethasone / Q000627:therapeutic use; D004205:Cromolyn Sodium / Q000627:therapeutic use; D006634:Histamine H1 Antagonists / Q000145:classification / Q000627:therapeutic use; D006801:Humans; D007073:Immunoglobulin E / Q000276:immunology; D007167:Immunotherapy; D014663:Nasal Decongestants / Q000627:therapeutic use*; D010109:Oxymetazoline / Q000627:therapeutic use*; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy* / Q000503:physiopathology
D006634:Histamine H1 Antagonists; D014663:Nasal Decongestants; D007073:Immunoglobulin E; D010109:Oxymetazoline; D001507:Beclomethasone; D004205:Cromolyn Sodium